LYMPHOMA, T-CELL
Clinical trials for LYMPHOMA, T-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough lymphoma: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard single-agent treatments in 150 adults with certain types of T-cell lymphoma that have come back or not responded to prior therapy. The goal is to see if soquelitinib can delay cancer progression better than current …
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
New hope for Tough-to-Treat blood cancer: experimental therapy MB-105 enters phase 2
Disease control Recruiting nowThis study tests an experimental drug, MB-105, in about 46 adults with a type of blood cancer called CD5-positive T-cell lymphoma that has come back or not responded to standard treatments. The main goals are to see if the drug is safe and how well it shrinks tumors. Participants…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated May 26, 2026 08:25 UTC
-
New drug may prevent lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib can help prevent T-cell lymphoma from returning and reduce graft-versus-host disease (GVHD) after a stem cell transplant. About 44 adults with T-cell lymphoma who are in remission after transplant will take ruxolitinib as a maintenanc…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated May 26, 2026 08:21 UTC
-
New hope for rare blood cancers: targeted drug shows promise
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with certain slow-growing but incurable blood cancers (T/NK-cell lymphomas) that have not responded to standard treatment. About 48 adults will receive the drug to see if it shrinks tumors and how safe it is. The goal is to co…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New hope for tough lymphomas: experimental drug STP938 enters human trials
Disease control Recruiting nowThis study tests a new drug called STP938 in adults with B-cell or T-cell lymphoma that has returned or not responded to at least two prior treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 180 participants will take the drug alone, first in…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE1, PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated May 18, 2026 12:03 UTC